Lipocine
LPCN
21 hedge funds and large institutions have $1.48M invested in Lipocine in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.23% more ownership
Funds ownership: 9.17% → 9.4% (+0.23%)
13% less funds holding
Funds holding: 24 → 21 (-3)
38% less capital invested
Capital invested by funds: $2.4M → $1.48M (-$916K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$239K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.3K |
| 3 |
Renaissance Technologies
New York
|
+$21.9K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$210 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$177 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$123K |
| 2 |
Two Sigma Investments
New York
|
-$55.6K |
| 3 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$44.2K |
| 4 |
BlackRock
New York
|
-$22.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.63K |
LPCN Hedge Fund Activity: Q3 2023 in Review
21 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2023, worth a combined $1.48M — down 38% from $2.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LPCN and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $239K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $123K sold.
- 21 institutional investors held Lipocine (LPCN) as of Q3 2023, down from 24 in Q2 2023.
- Funds reported $1.48M of Lipocine stock for Q3 2023, down 38% quarter-over-quarter.
- 2 funds opened new Lipocine positions in Q3 2023 and 5 closed out, a net change of -3 holders.
- The largest Lipocine buyer in Q3 2023 was Two Sigma Advisers, an estimated $239K added.
- The largest Lipocine seller in Q3 2023 was Bridgeway Capital Management, an estimated $123K sold.
Based on aggregated 13F filings for Q3 2023.